Around 6 million Australians are living with hypertension, and according to data compiled by Hypertension Australia, only about one-third of them have their condition adequately controlled. That figure puts Australia behind Germany, Canada, and the United States on a measure that directly affects stroke risk, heart failure rates, and premature death. The gap between how many people have high blood pressure and how many actually manage it is the central problem that a new generation of home monitoring devices promises to close.
The good news is that options have never been so varied. The more cautious news is that variety and reliability are not the same thing.
The case for monitoring at home
Clinical evidence has long supported home blood pressure monitoring as a complement to GP visits. The Australian Institute of Health and Welfare notes that in 2022, more than one in five Australian adults had high measured blood pressure, a rate that rises sharply with age, reaching above 42 per cent in those aged 75 and over. Regular self-measurement gives patients and their doctors a richer picture than a single clinic reading can provide.
There is also the question of "white coat" syndrome, the well-documented phenomenon where blood pressure spikes in a clinical setting and can lead to over-diagnosis. Round-the-clock ambulatory blood pressure monitoring can effectively diagnose conditions such as white coat syndrome and masked hypertension, yet it is rarely used by physicians. Home monitoring, done consistently and correctly, helps fill that gap at a fraction of the cost.
What the evidence says about device types
Not all monitors are created equal, and the distinctions matter. Validated upper-arm cuff monitors remain the clinical benchmark. Consumer Reports tests blood pressure monitors on real people and compares the results with those of a mercury sphygmomanometer, the device considered the gold standard in blood pressure testing. Devices from brands such as Omron and A&D consistently score well on accuracy in independent testing, though correct technique, including proper cuff sizing and posture, remains critical regardless of the hardware.
Wrist and finger monitors tend to perform less reliably. The American Heart Association does not recommend them as primary monitoring tools, and independent reviewers have consistently found greater variability in their readings compared with upper-arm devices.
Then there is the fastest-growing category: cuffless wearables. Smartwatches, rings, patches, and fingertip monitors have proliferated rapidly, and their appeal is obvious. Over the past decade, the number and type of cuffless devices to measure blood pressure, such as smartwatches, rings, patches, and fingertip monitors, have increased significantly. Apple's Watch Series 11 now includes a hypertension notification feature, and Samsung, Huawei, and others have either launched or signalled similar capabilities.
Apple's hypertension notification feature uses an optical sensor to look for patterns in how blood vessels respond to a heartbeat over about 30 days; if it sees a pattern that suggests high blood pressure, users receive a notification recommending they confirm the reading with a home blood pressure cuff and meet with their doctor. That is a meaningful distinction: the company is careful to frame it as a notification, not a diagnosis.
The accuracy gap in wearables
The enthusiasm for wearable technology should be tempered by the science. In December 2025, the American Heart Association published a scientific statement in its journal Hypertension making clear that cuffless devices show great promise as alternatives to traditional arm-cuff monitors, but they are not yet proven accurate enough to diagnose high blood pressure or guide treatment decisions. A parallel review published in JAMA Cardiology found that many devices available to consumers on phones, watches, rings, and patches need further testing and validation; the devices also face challenges relating to accuracy, calibration, and user variability, with some performing better in younger, healthier populations than in elderly or critically ill patients.
Research published in Hypertension Research in 2026 was even more direct, concluding that there is no convincing evidence that any cuffless blood pressure technology has adequate accuracy as required for clinical use, and scientific societies do not recommend them.
Most blood pressure smartwatches in 2025 still require regular calibration against a measurement from a traditional, validated medical cuff to maintain any semblance of accuracy, which rather undercuts the convenience argument.
Australia's broader detection problem
Analysis shows that after 2010, approximately 31 per cent of Australian adults were living with hypertension; alarmingly, only about half of those individuals were aware of their condition or receiving treatment, and merely one-third had their blood pressure adequately controlled. Research from The George Institute for Global Health at UNSW has confirmed that high blood pressure persists as the leading cause of death in Australia, reinforcing the need for a concerted national effort to shift the dial on blood pressure control.
Australia's control rate of 34 per cent is significantly lower than Germany at 58 per cent, Canada at 50 per cent, and the United States at 54 per cent. That is a sobering comparison for a country with universal health coverage and a functioning primary care system.
There is a reasonable argument, then, that anything which increases the frequency and ease of blood pressure checking is a net social good, even if the technology is imperfect. The snapshot readings of traditional cuff-based monitors often miss dangerous spikes or drops; continuous blood pressure monitoring captures real-time fluctuations. If a smartwatch nudges someone to see their GP after detecting a suspicious pattern, that is a genuine benefit the older model of annual check-ups cannot replicate.
A measured approach
The practical advice from clinicians and researchers is consistent: for anyone who wants a reliable home reading to share with their doctor, a validated upper-arm cuff monitor remains the appropriate choice. For those who use a smartwatch and receive a hypertension notification, the right response is to treat it as a prompt, not a diagnosis, confirm the reading with a proper cuff, and seek medical review.
Wearable blood pressure monitoring technologies are maturing, with growing potential in preventive cardiovascular medicine, but clinical implementation is limited by varying accuracy, the need for calibration, and a lack of standardisation; further validation and longitudinal studies are needed to establish their role in cardiovascular risk prediction.
Given that hypertension is Australia's single largest cardiovascular risk factor, the goal of getting more people to know their numbers is the right one. The device they use to get there should be chosen with realistic expectations about what it can and cannot tell them.